Diagnostic delay in PG is linked to longer healing times, even after adjusting for ulcer size and comorbidities. Our latest response highlights these findings and the need for more research to improve patient outcomes. Read more here: https://t.co/sAdQP9h1IH
Please join me at the Annual Meeting for the @MedDermSoc in San Diego: 2024 Annual Meeting Agenda - (https://t.co/YfqpB1jklp). Very excited about this invitation "Pyoderma Gangrenosum: Current Landscape and Future Perspectives From UPGRADE"
I am very honored and excited to be the discussant for the upcoming 2024 Harvard Med Derm Retreat @bwhdermatology @HMSCombinedDerm@MostaghimiLab@DrMeganNoe See you all on Tuesday, March 26th at Brigham and Women's Hospital (BWH) in Boston
We are working together in #UPGRADE paving a way forward to elevate the standards of #pyodermagangrenosum clinical trials; the core domain set for PG trials include now clinical signs, quality of life and pain @BrJDermatol@MedDermSoc#dermtwitter
https://t.co/4c3aPKKCyV
I am very excited to share our most recent study https://t.co/huCibXg90k. We showed that a 2-point improvement in pain based on a numeric rating scale may indicate that #pyodermagangrenosum patients are responding to treatment @JAMADerm@MedDermSoc#medtwitter#RareDisease
Thanks to @MedDermSoc for supporting this project through the research committee. Determining the severity features of pyoderma gangrenosum are the first step to develop clinical guidelines @BrJDermatol#dermtwitter#RareDiseases
https://t.co/Ws6TsyDfRw
“The rarity of PG combined with the difficulty of its diagnosis and treatment make it all the more important for
providers to understand the legal challenges faced by patients with this condition.” https://t.co/eOTUXB9eoC @OHSUNews@uamshealth@KTS_Law@ThePGguy